Menu

Eliza O’Neill’s Journey with Sanfilippo Syndrome and Gene Therapy

2 weeks ago 0

In 2015, the O’Neill family posed for a photo: Glenn, Beckham, Cara, and young Eliza. Eliza faces Sanfilippo syndrome, a rare genetic disorder. Before her diagnosis, Eliza cherished accessorizing with items like scarves or hats. Cara O’Neill, her mother and a pediatrician in South Carolina, recalls Eliza playing around in her high heels. But at age three, Eliza lagged in achieving developmental milestones. Her parents learned she had pragmatic speech delay, with many words learned but rarely used in social settings.

In 2013, a colleague suggested a test for metabolic disorders, revealing the presence of Sanfilippo syndrome. The disorder prevents the breakdown of heparin sulfate, essential for cell function, leading to severe complications. Sanfilippo sufferers lose speech and mobility, experience seizures, and generally don’t survive beyond their teens. Following the diagnosis, Glenn O’Neill realized the urgency required: “Whatever we need to do, we need to do it now.”

Seeking Treatment

Researcher Haiyan Fu at Nationwide Children’s Hospital in Ohio explored gene therapy for Sanfilippo starting in the late 1990s. Her approach involved using a virus to deliver a functional gene copy to patient cells. Fu remained committed: “If we treat early, it could be potentially a cure.” Though funding was precarious, eight patient foundations aided Fu until a human trial emerged.

Funding the Trial

Clinical trials proved costly, but Glenn O’Neill ventured on the internet for fundraising ideas. Filmmaker Benjamin Von Wong assisted them by creating a viral video, “Saving Eliza,” in 2014. The campaign raised $1 million in weeks, eventually reaching $2 million. Funding enabled the May 2016 human trial. Promising results caught biotech industry’s attention, leading Ultragenyx to acquire gene therapy rights in 2022. They presented data to the FDA, which approved the therapy, termed Fayuvi, in September.

CEO Emil Kakkis emphasized early treatment: “The younger the child is, the better the treatment works.” Fayuvi costs about $4 million, tying for the second-most-expensive gene therapy, according to 46brooklyn. Yet, Ultragenyx pledged patient treatment assurance.

Fu witnessed mixed emotions following FDA approval. The long journey felt bittersweet amid messages from families, some having lost children. She remarked, “It shouldn’t take this long.” Today, Eliza, nearly 17, remains significant in gene therapy advancement. Though treated at six and unable to regain speech, she communicates using cards and devices. Eliza attends school, swims, and floats on pool noodles. Glenn O’Neill reflects, “I feel proud of her…she’s very lucky.”

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *